Suggested remit: To appraise the clinical and cost effectiveness of vanzacaftor–tezacaftor–deutivacaftor within its marketing authorisation for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
Cost Comparison Standard
|
| ID number |
6372
|
Provisional Schedule
| Expected publication |
21 August 2025 |
Project Team
Email enquiries
| External Assessment Group |
Kleijnen Systematic Reviews Ltd |
Stakeholders
| Companies sponsors |
Vertex Pharmaceuticals |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Cystic Fibrosis Trust |
| Professional groups |
Association of Chartered Physiotherapists in Cystic Fibrosis |
| |
British Dietetic Association |
| |
British Paediatric Respiratory Society |
| |
British Thoracic Society |
| |
Cystic Fibrosis Nursing Association |
| |
Neonatal and Paediatric Pharmacists Group (NPPG) |
| |
Royal College of Physicians |
| |
UK Clinical Pharmacy Association |
| |
UK Cystic Fibrosis Medical Association |
| |
UK Cystic Fibrosis Pharmacy Group |
| |
UK Psychosocial Professionals in Cystic Fibrosis Group |
| Associated public health groups |
None |
| Comparator companies |
Vertex Pharmaceuticals (elexacaftor, lumcaftor and ivacaftor) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health - Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
NHS Wales Joint Commissioning Committee |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| Relevant research groups |
Cochrane Cystic Fibrosis and Genetic Disorders Group |
|
Date
|
Update
|
|
23 January 2025
|
Invitation to participate |
|
17 September 2024 - 15 October 2024
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6372 |
|
17 September 2024
|
In progress. Scoping commencing |
|
17 September 2024
|
In progress. Scoping commencing |
|
26 July 2024
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
|
12 October 2023
|
Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual